JPH06508762A - 卵黄嚢幹細胞 - Google Patents

卵黄嚢幹細胞

Info

Publication number: JPH06508762A
Authority: JP; Japan
Prior art keywords: cells; yolk sac; yolk; stem cells; animal
Prior art date: 1991-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP5502931A

Other languages

English (en)

Japanese (ja)

Inventor

イー．ワグナー，トーマス

アントクザック，マイケル　アール．

Original Assignee

エディソン　アニマル　バイオテクノロジー　センター，オハイオ　ユニバーシティー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-15

Filing date

1992-07-14

Publication date

1994-10-06

1992-07-14 Application filed by エディソン　アニマル　バイオテクノロジー　センター，オハイオ　ユニバーシティー filed Critical エディソン　アニマル　バイオテクノロジー　センター，オハイオ　ユニバーシティー

1994-10-06 Publication of JPH06508762A publication Critical patent/JPH06508762A/ja

Status Pending legal-status Critical Current

Links

210000001325 yolk sac Anatomy 0.000 title claims description 84
210000000130 stem cell Anatomy 0.000 title claims description 55
210000004027 cell Anatomy 0.000 claims description 258
238000000034 method Methods 0.000 claims description 47
241001465754 Metazoa Species 0.000 claims description 42
238000001727 in vivo Methods 0.000 claims description 34
210000000601 blood cell Anatomy 0.000 claims description 33
238000000338 in vitro Methods 0.000 claims description 23
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 18
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 18
102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 14
108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 14
230000000735 allogeneic effect Effects 0.000 claims description 14
230000003394 haemopoietic effect Effects 0.000 claims description 13
210000004369 blood Anatomy 0.000 claims description 12
239000008280 blood Substances 0.000 claims description 12
230000035935 pregnancy Effects 0.000 claims description 12
230000015572 biosynthetic process Effects 0.000 claims description 11
210000000777 hematopoietic system Anatomy 0.000 claims description 11
108010002386 Interleukin-3 Proteins 0.000 claims description 10
241001494479 Pecora Species 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
241000283707 Capra Species 0.000 claims description 9
102100028471 Eosinophil peroxidase Human genes 0.000 claims description 8
241000282412 Homo Species 0.000 claims description 6
238000012258 culturing Methods 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
230000024245 cell differentiation Effects 0.000 claims description 5
239000003102 growth factor Substances 0.000 claims description 5
108010002350 Interleukin-2 Proteins 0.000 claims description 3
108010092408 Eosinophil Peroxidase Proteins 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 6
230000001413 cellular effect Effects 0.000 claims 5
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
230000001747 exhibiting effect Effects 0.000 claims 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 claims 1
102000000588 Interleukin-2 Human genes 0.000 claims 1
102000000646 Interleukin-3 Human genes 0.000 claims 1
235000013399 edible fruits Nutrition 0.000 claims 1
241000699666 Mus <mouse, genus> Species 0.000 description 55
241000699670 Mus sp. Species 0.000 description 50
210000002969 egg yolk Anatomy 0.000 description 48
210000001539 phagocyte Anatomy 0.000 description 32
239000000427 antigen Substances 0.000 description 29
108091007433 antigens Proteins 0.000 description 29
102000036639 antigens Human genes 0.000 description 29
210000004170 yolk cell Anatomy 0.000 description 29
210000003754 fetus Anatomy 0.000 description 25
230000007774 longterm Effects 0.000 description 24
102000002322 Egg Proteins Human genes 0.000 description 22
108010000912 Egg Proteins Proteins 0.000 description 22
210000001185 bone marrow Anatomy 0.000 description 22
235000013345 egg yolk Nutrition 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 22
230000004069 differentiation Effects 0.000 description 19
108700018351 Major Histocompatibility Complex Proteins 0.000 description 18
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 18
210000001744 T-lymphocyte Anatomy 0.000 description 17
210000000496 pancreas Anatomy 0.000 description 17
210000001519 tissue Anatomy 0.000 description 16
238000011282 treatment Methods 0.000 description 15
210000002257 embryonic structure Anatomy 0.000 description 14
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
230000011132 hemopoiesis Effects 0.000 description 13
210000002540 macrophage Anatomy 0.000 description 12
238000002054 transplantation Methods 0.000 description 12
210000003719 b-lymphocyte Anatomy 0.000 description 11
238000011161 development Methods 0.000 description 11
230000018109 developmental process Effects 0.000 description 11
210000003743 erythrocyte Anatomy 0.000 description 11
239000002158 endotoxin Substances 0.000 description 10
210000003958 hematopoietic stem cell Anatomy 0.000 description 10
229920006008 lipopolysaccharide Polymers 0.000 description 10
210000004185 liver Anatomy 0.000 description 10
241000894007 species Species 0.000 description 10
235000013601 eggs Nutrition 0.000 description 9
230000012010 growth Effects 0.000 description 9
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 8
206010052779 Transplant rejections Diseases 0.000 description 8
229960002092 busulfan Drugs 0.000 description 8
239000002609 medium Substances 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
238000012546 transfer Methods 0.000 description 8
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
238000000684 flow cytometry Methods 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 7
210000001161 mammalian embryo Anatomy 0.000 description 7
238000012360 testing method Methods 0.000 description 7
210000004748 cultured cell Anatomy 0.000 description 6
230000000694 effects Effects 0.000 description 6
210000004379 membrane Anatomy 0.000 description 6
239000012528 membrane Substances 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
230000004044 response Effects 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
210000004291 uterus Anatomy 0.000 description 6
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
206010068051 Chimerism Diseases 0.000 description 5
101150052863 THY1 gene Proteins 0.000 description 5
210000002798 bone marrow cell Anatomy 0.000 description 5
238000010322 bone marrow transplantation Methods 0.000 description 5
230000013020 embryo development Effects 0.000 description 5
239000012634 fragment Substances 0.000 description 5
238000002955 isolation Methods 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
210000005259 peripheral blood Anatomy 0.000 description 5
239000011886 peripheral blood Substances 0.000 description 5
206010061598 Immunodeficiency Diseases 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
210000003714 granulocyte Anatomy 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
230000006698 induction Effects 0.000 description 4
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
229950002929 trinitrophenol Drugs 0.000 description 4
239000013598 vector Substances 0.000 description 4
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 3
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
241001529936 Murinae Species 0.000 description 3
229910000831 Steel Inorganic materials 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
238000002679 ablation Methods 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000005875 antibody response Effects 0.000 description 3
230000011712 cell development Effects 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
210000002308 embryonic cell Anatomy 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
230000005714 functional activity Effects 0.000 description 3
208000024908 graft versus host disease Diseases 0.000 description 3
210000003677 hemocyte Anatomy 0.000 description 3
229940000351 hemocyte Drugs 0.000 description 3
230000036737 immune function Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
230000000998 lymphohematopoietic effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000003593 megakaryocyte Anatomy 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
210000002894 multi-fate stem cell Anatomy 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000010959 steel Substances 0.000 description 3
230000009466 transformation Effects 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
238000011740 C57BL/6 mouse Methods 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
206010064912 Malignant transformation Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
208000031513 cyst Diseases 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000034994 death Effects 0.000 description 2
210000003785 decidua Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000012137 double-staining Methods 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
208000016361 genetic disease Diseases 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
210000004565 granule cell Anatomy 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000036212 malign transformation Effects 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000035800 maturation Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
230000005868 ontogenesis Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
238000002689 xenotransplantation Methods 0.000 description 2
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108700031361 Brachyury Proteins 0.000 description 1
241000219198 Brassica Species 0.000 description 1
235000003351 Brassica cretica Nutrition 0.000 description 1
235000003343 Brassica rupestris Nutrition 0.000 description 1
102000013925 CD34 antigen Human genes 0.000 description 1
108050003733 CD34 antigen Proteins 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
102100025390 Integrin beta-2 Human genes 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
-1 LFA Proteins 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
101000962498 Macropis fulvipes Macropin Proteins 0.000 description 1
102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
241000233855 Orchidaceae Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
108010067035 Pancrelipase Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
241000287462 Phalacrocorax carbo Species 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
102000015215 Stem Cell Factor Human genes 0.000 description 1
108010039445 Stem Cell Factor Proteins 0.000 description 1
208000002903 Thalassemia Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
238000002669 amniocentesis Methods 0.000 description 1
210000001691 amnion Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical group [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
210000000625 blastula Anatomy 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000001736 capillary Anatomy 0.000 description 1
230000022159 cartilage development Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
238000004891 communication Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000012136 culture method Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
238000002224 dissection Methods 0.000 description 1
230000009228 embryo fetal development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
210000005161 hepatic lobe Anatomy 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000007726 management method Methods 0.000 description 1
210000003519 mature b lymphocyte Anatomy 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000002198 morula cell Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
235000010460 mustard Nutrition 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
101150005646 old gene Proteins 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
108010052044 polyclonal B cell activator Proteins 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
210000002763 pyramidal cell Anatomy 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
210000003934 vacuole Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Reproductive Health (AREA)
Developmental Biology & Embryology (AREA)
Gynecology & Obstetrics (AREA)
Hematology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pregnancy & Childbirth (AREA)
Virology (AREA)
Epidemiology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

JP5502931A 1991-07-15 1992-07-14 卵黄嚢幹細胞 Pending JPH06508762A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US73025091A	1991-07-15	1991-07-15
US730,250		1991-07-15
US88037592A	1992-05-08	1992-05-08
US880,375		1992-05-08
PCT/US1992/005918 WO1993002182A1 (en)	1991-07-15	1992-07-14	Yolk sac stem cells

Publications (1)

Publication Number	Publication Date
JPH06508762A true JPH06508762A (ja)	1994-10-06

Family

ID=27112018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP5502931A Pending JPH06508762A (ja)	1991-07-15	1992-07-14	卵黄嚢幹細胞

Country Status (5)

Country	Link
EP (1)	EP0594725A4 (de)
JP (1)	JPH06508762A (de)
AU (1)	AU661709B2 (de)
CA (1)	CA2113555A1 (de)
WO (1)	WO1993002182A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744347A (en) *	1987-01-16	1998-04-28	Ohio University Edison Biotechnology Institute	Yolk sac stem cells and their uses
US5437766A (en) *	1993-10-22	1995-08-01	The Procter & Gamble Company	Multi-ply facial tissue paper product comprising biodegradable chemical softening compositions and binder materials
US5599705A (en) *	1993-11-16	1997-02-04	Cameron; Robert B.	In vitro method for producing differentiated universally compatible mature human blood cells
CN120290455A (zh) *	2018-11-08	2025-07-11	整合培育株式会社	动物细胞增殖促进剂、动物细胞培养用培养基和动物细胞培养装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4497796A (en) *	1980-03-26	1985-02-05	The Regents Of The University Of California	Gene transfer in intact mammals
US5032407A (en) *	1987-01-16	1991-07-16	Ohio University Edison Animal Biotechnology Center	Gene transfer using transformed, neodetermined, embryonic cells

1992
- 1992-07-14 EP EP19920915474 patent/EP0594725A4/de not_active Withdrawn
- 1992-07-14 WO PCT/US1992/005918 patent/WO1993002182A1/en not_active Ceased
- 1992-07-14 CA CA002113555A patent/CA2113555A1/en not_active Abandoned
- 1992-07-14 JP JP5502931A patent/JPH06508762A/ja active Pending
- 1992-07-14 AU AU23248/92A patent/AU661709B2/en not_active Ceased

Also Published As

Publication number	Publication date
CA2113555A1 (en)	1993-02-04
AU2324892A (en)	1993-02-23
EP0594725A4 (de)	1994-11-30
AU661709B2 (en)	1995-08-03
EP0594725A1 (de)	1994-05-04
WO1993002182A1 (en)	1993-02-04

Publication	Publication Date	Title
US6093531A (en)	2000-07-25	Generation of hematopoietic cells from multipotent neural stem cells
AU701752B2 (en)	1999-02-04	Yolk sac stem cells and their uses
US20040106195A1 (en)	2004-06-03	Method for identification of cell growth or differentiation factors
US20030124091A1 (en)	2003-07-03	Endothelial cell derived hematopoietic growth factor
WO2012133948A1 (ja)	2012-10-04	生体組織から単離できるssea-3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
US6821513B1 (en)	2004-11-23	Method for enhancing hematopoiesis
US20030100107A1 (en)	2003-05-29	Compositions and methods for generating differentiated human cells
Muench et al.	2004	Stem cell transplantation in the fetus
JPH06508762A (ja)	1994-10-06	卵黄嚢幹細胞
WO1999003980A1 (en)	1999-01-28	Agm-derived stroma cells
Murawska et al.	1991	Differential Kinetics of Various Subsets of Thymic Bone Marrow‐Derived Stromal Cells in Rat Chimeras
AU2003200256B2 (en)	2006-02-23	Generation of hematopoietic cells from multipotent neural stem cells
Péault et al.	1999	Haematopoietic stem cell emergence and development in the human embryo and fetus; perspectives for blood cell therapies in utero
JP2001037471A (ja)	2001-02-13	移植可能な造血細胞の産生法
KR101404903B1 (ko)	2014-06-11	인간 혈액 유래 혈구 세포괴를 포함하는 림프관 형성 촉진용 약학적 조성물
JP2003530899A (ja)	2003-10-21	造血を増強する方法
KR20070113694A (ko)	2007-11-29	조혈모세포 생착 촉진용 조성물
Thompson	2014	Immunogenicity of Embryonic Stem Cell Derived Hematopoietic Progenitors
JPWO1999003980A1 (ja)	2002-08-06	Ａｇｍ領域由来ストローマ細胞